Ever Supreme Bio Technology Co., Ltd (TPEX:6712)

Market Cap	12.26B -15.5%
Revenue (ttm)	1.02B +9.0%
Net Income	429.43M +16.9%
EPS	4.88 +17.9%
Shares Out	87.60M
PE Ratio	28.69
Forward PE	22.76
Dividend	3.50 (2.50%)
Ex-Dividend Date	Apr 16, 2026

Volume	127,692
Average Volume	175,967
Open	141.00
Previous Close	141.00
Day's Range	140.00 - 141.50
52-Week Range	138.50 - 188.00
Beta	0.52
RSI	41.05
Earnings Date	Apr 14, 2026

About TPEX:6712

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company’s products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine (ADCV01), a drug candidate in Phase II clinical trials for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6712

Financial Performance

In 2025, TPEX:6712's revenue was 1.02 billion, an increase of 8.96% compared to the previous year's 933.81 million. Earnings were 429.43 million, an increase of 16.93%.